Myriad Genetics Inc. (MYGN)
14.96
0.06 (0.40%)
At close: Feb 20, 2025, 3:59 PM
15.20
1.64%
After-hours: Feb 20, 2025, 06:05 PM EST
undefined% (undefined)
| Bid | 13.93 |
| Market Cap | 1.36B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.28 |
| PE Ratio (ttm) | -11.68 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 16 |
| Volume | 898,021 |
| Avg. Volume (20D) | 1,052,100 |
| Open | 14.82 |
| Previous Close | 14.90 |
| Day's Range | 14.77 - 15.19 |
| 52-Week Range | 12.04 - 29.30 |
| Beta | undefined |
About MYGN
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing...
Industry Medical - Diagnostics & Research
Sector Healthcare
IPO Date Oct 6, 1995
Employees 2,700
Stock Exchange NASDAQ
Ticker Symbol MYGN
Website https://myriad.com
Analyst Forecast
According to 13 analyst ratings, the average rating for MYGN stock is "Hold." The 12-month stock price forecast is $20, which is an increase of 33.73% from the latest price.
Buy 30.77%
Hold 46.15%
Sell 23.08%
Next Earnings Release
Myriad Genetics Inc. is scheduled to release its earnings on Feb 24, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+11.92%
Myriad Genetics shares are trading higher on possi...
Unlock content with
Pro Subscription
5 months ago
-7.65%
Myriad Genetics shares are trading lower after the company announced that it discontinued the second part of its study due to the disparities between the GeneSight Group and control group.
